Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,009 | 121 | 96.8% |
| Education | $99.95 | 1 | 3.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $263.49 | 12 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $262.77 | 9 | $0 (2024) |
| Eisai Inc. | $248.73 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $228.24 | 9 | $0 (2024) |
| Gilead Sciences, Inc. | $218.29 | 8 | $0 (2024) |
| Daiichi Sankyo Inc. | $188.67 | 7 | $0 (2024) |
| Incyte Corporation | $139.88 | 7 | $0 (2024) |
| Stemline Therapeutics Inc. | $138.85 | 5 | $0 (2024) |
| Merck Sharp & Dohme LLC | $138.21 | 6 | $0 (2024) |
| PUMA BIOTECHNOLOGY, INC. | $136.46 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,090 | 120 | Novartis Pharmaceuticals Corporation ($263.49) |
| 2021 | $18.45 | 2 | Ironwood Pharmaceuticals, Inc ($11.67) |
All Payment Transactions
122 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Oncology | ||||||
| 12/24/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: Oncology | ||||||
| 12/23/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.19 | General |
| 12/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $30.55 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: Oncology | ||||||
| 12/01/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $29.31 | General |
| Category: Hematology/Oncology | ||||||
| 11/22/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $23.85 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $28.18 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.66 | General |
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $29.24 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 10/25/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.90 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $28.65 | General |
| Category: Oncology | ||||||
| 10/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: Oncology | ||||||
| 10/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.79 | General |
| 10/09/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $29.22 | General |
| 10/08/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 122 | 123 | $26,006 | $6,351 |
| 2022 | 9 | 564 | 611 | $97,624 | $30,345 |
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 51 | 52 | $10,608 | $2,788 | 26.3% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 27 | 27 | $5,361 | $1,358 | 25.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $5,757 | $1,276 | 22.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 14 | $4,214 | $905.44 | 21.5% |
| 81003 | Automated urinalysis test | Office | 2023 | 11 | 11 | $66.00 | $24.20 | 36.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 292 | 305 | $62,220 | $20,347 | 32.7% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 99 | 101 | $20,056 | $5,060 | 25.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 22 | 22 | $6,622 | $2,068 | 31.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 23 | 24 | $3,000 | $1,135 | 37.8% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 30 | 60 | $1,980 | $975.18 | 49.3% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 12 | 12 | $876.00 | $241.82 | 27.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 19 | 19 | $1,102 | $182.44 | 16.6% |
| 81002 | Urinalysis, manual test | Office | 2022 | 50 | 51 | $459.00 | $171.71 | 37.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 17 | 17 | $1,309 | $163.06 | 12.5% |
About Michael Eng
Michael Eng is a Physician Assistant healthcare provider based in Corona, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/17/2018. The National Provider Identifier (NPI) number assigned to this provider is 1053882076.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Eng has received a total of $3,109 in payments from pharmaceutical and medical device companies, with $3,090 received in 2024. These payments were reported across 122 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($3,009).
As a Medicare-enrolled provider, Eng has provided services to 686 Medicare beneficiaries, totaling 734 services with total Medicare billing of $36,696. Data is available for 2 years (2022–2023), covering 14 distinct procedure/service records.
Practice Information
- Specialty Physician Assistant
- Location Corona, CA
- Active Since 12/17/2018
- Last Updated 01/10/2019
- Taxonomy Code 363A00000X
- Entity Type Individual
- NPI Number 1053882076
Products in Payments
- Lenvima (Drug) $248.73
- Enhertu (Drug) $188.67
- FRUZAQLA (Drug) $185.15
- SARCLISA (Biological) $169.37
- IMFINZI (Biological) $151.16
- Orserdu (Drug) $138.85
- KEYTRUDA (Biological) $138.21
- VERZENIO (Drug) $134.77
- JAKAFI (Drug) $111.63
- Fabhalta (Drug) $90.35
- AYVAKIT (Drug) $88.67
- FOTIVDA (Drug) $85.94
- PLUVICTO (Drug) $77.04
- KISQALI (Drug) $76.68
- BESREMI (Drug) $58.46
- ALUNBRIG (Drug) $54.43
- ENHERTU (Biological) $54.18
- GILOTRIF (Drug) $53.90
- Onivyde (Drug) $44.63
- Phesgo (Biological) $34.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physician Assistant Doctors in Corona
Taryn Sommers, Pa, PA
Physician Assistant — Payments: $16,841
Tom Ku, P.a.-C, P.A.-C
Physician Assistant — Payments: $13,352
Gregory Lynch, Pa-C, PA-C
Physician Assistant — Payments: $8,205
Ruoru Wong, Pa-C, PA-C
Physician Assistant — Payments: $4,899
Ms. Hayley Lynam, Pa-C, PA-C
Physician Assistant — Payments: $3,737
Christian Diaz
Physician Assistant — Payments: $2,906